|
|
 |
|
Viewing report
|
|
|
|
Optimizing Genomics Asset Management for High ROI - Evaluating Strategies to Support the Bio/Pharma Value Chain
Datamonitor, Oct 2004, Pages: 90
Introduction
The need to overcome the pharma industrys pipeline productivity crisis is forcing the genomics innovators and their partners to reshape their portfolio management. New asset allocation strategies and valuation methodologies are needed to support the evolution to a new business model emphasizing investment in technological diversification.
Scope
Insight into the dynamics of the genomics sector, as it diversifies to meet the challenge of the evolving bio/pharma supply chain
Survival strategies for potential postgenomics drug developers and successful exit strategies for failed genomics businesses
Novel portfolio management and option based asset valuation to support postgenomics drug developers, genomics licensees and innovators
Highlights
The early wave of the genomics revolution witnessed a spectacular stock value decline. This was caused by the lack of transparency between the industrys innovating, investing and licensing arms, and by a high degree of speculation related to unrealistic market generation targets and lack of understanding of the technological complexities.
The new wave of innovation is focusing on gene functionalities, population genomics, chemo- and pharmacogenomics. Drug developers should continue integrating well-defined genomics assets into their supply chains, work to maximize successful target validation and optimize alliance networks to ensure asset co-evolution and diversification.
Conventional discount flow-based asset valuation cannot describe the complexity of each genomics asset. Therefore, blending quantitative real option based and qualitative multifactorial asset analysis models can offer flexible long-term asset allocation and a number of capital growth opportunities hidden in genomics assets.
Reasons to Purchase
Understand the dynamics behind the early genomics devaluation, and develop winning business survival and successful postgenomics exit strategies
Gain insight into how the new wave of genomics diversification helps the bio/pharma supply chain to recover from its current productivity crisis
Improve genomics project valuation by combining novel multidimensional asset analysis for less supply chain complexity, with real option based methods
Customers who bought this item also bought
Optimizing Genomics Asset Management for High ROI - Evaluating Strategies to Support the Bio/Pharma Value Chain
Genomics World Markets 2008
Has Genomics Failed to Deliver?
The Global Functional Genomics Industry
Weedy and Invasive Plant Genomics
Genomics: Pharmaceutical Investment, Integration and Partnerships
Genomics in Drug Discovery and Development
Genomics Players: From Discovery to Integration- Business and Technology Assessment, 2002
Drug Targets from Genomics: Evolving Tools for Discovery
PharmaVitae 2001: Celera Genomics
Understanding Genomics and Global Health Impacts
Transforming Drug Discovery through Genomics and Proteomics
|
|
|
|
